Related Experiment Video
Updated: Nov 11, 2025
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.6K
A Validated Register-Based Algorithm to Identify Patients Diagnosed with Recurrence of Malignant Melanoma in Denmark
Linda Aagaard Rasmussen1, Henry Jensen1, Line Flytkjaer Virgilsen1
1Research Centre for Cancer Diagnosis in Primary Care (CaP), Research Unit for General Practice, Aarhus, Denmark.
Clinical Epidemiology
|March 24, 2021
Summary
A new algorithm accurately identifies malignant melanoma recurrence using Danish health registers. This enables population-level studies on disease-free survival and diagnostic pathways for melanoma patients.
Area of Science:
- Oncology
- Public Health
- Health Informatics
Background:
- Cancer recurrence data is limited outside clinical trials, hindering generalizability.
- Population-level evidence is crucial for understanding outcomes in diverse patient groups.
- Malignant melanoma recurrence requires accurate identification for effective management.
Purpose of the Study:
- To develop and validate a register-based algorithm for identifying malignant melanoma recurrence.
- To assess the algorithm's accuracy against a gold standard.
- To enable population-level analysis of melanoma recurrence.
Main Methods:
- Utilized diagnosis and procedure codes from the Danish National Patient Register.
- Incorporated pathology results from the Danish National Pathology Register.
- Validated against medical records in the Danish Melanoma Database (gold standard).
Main Results:
- The algorithm achieved high accuracy: 93.7% sensitivity and 99.2% specificity.
- Positive predictive value was 86.4%, and negative predictive value was 99.6%.
- Excellent agreement (Lin's concordance coefficient 0.992) for recurrence dates.
Conclusions:
- The validated algorithm reliably identifies malignant melanoma recurrence and its timing.
- Enables generation of population-level evidence on disease-free survival.
- Supports improved understanding of diagnostic pathways for melanoma recurrence.
